Published in Eur J Clin Invest on August 01, 2004
The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients | NCT00119769
Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol (2010) 1.34
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab (2001) 3.09
The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia (2007) 3.07
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes (2001) 3.06
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev (2000) 3.01
Inhibition of insulin secretion by somatostatin. Lancet (1973) 2.58
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. N Engl J Med (1990) 2.46
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab (2003) 2.41
Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet (1992) 2.40
Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med (2011) 2.30
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr (1992) 2.29
The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia (2009) 2.25
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med (2010) 2.07
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med (2008) 2.04
[Travelers' diarrhea]. Ugeskr Laeger (1993) 2.03
[New discoveries about the cause of diabetes. Type 2 diabetes mellitus changed to "obesity-dependent diabetes mellitus"]. Ugeskr Laeger (2001) 2.02
The neural basis of the complex mental task of meditation: neurotransmitter and neurochemical considerations. Med Hypotheses (2003) 2.00
Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS). Br Med J (Clin Res Ed) (1985) 1.93
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J (2004) 1.90
Differential distribution of Australia-antigen-associated particles in patients with liver diseases and normal carriers. N Engl J Med (1973) 1.86
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia (2002) 1.86
Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia (2005) 1.85
Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia (2009) 1.81
Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem J (1995) 1.81
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia (2008) 1.75
Evidence for a feedback inhibition of insulin on insulin secretion in the isolated, perfused canine pancreas. Diabetes (1971) 1.70
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest (1991) 1.67
Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. Br Med J (Clin Res Ed) (1987) 1.65
Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab (2012) 1.63
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care (1999) 1.62
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Engl J Med (1971) 1.60
Severe acquired immunodeficiency in European homosexual men. Br Med J (Clin Res Ed) (1982) 1.59
Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia (2005) 1.58
Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia (2012) 1.52
Liver-cell-membrane autoantibody specific for inflammatory liver diseases. Br Med J (1977) 1.48
Adrenergic receptors and the secretion of glucagon and insulin from the isolated, perfused canine pancreas. J Clin Invest (1973) 1.47
Secretion of glucagon from the isolated, perfused canine pancreas. J Clin Invest (1971) 1.47
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med (2008) 1.47
Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology (1996) 1.45
Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood (2001) 1.44
Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg (2012) 1.42
Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (1994) 1.41
Effects of heparin on renal morphology and albuminuria in experimental diabetes. Am J Physiol (1996) 1.40
Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand (1981) 1.40
Insulin-like growth factor I - a novel biomarker of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg (2011) 1.40
[Exposure to blood and risk of infection among health personnel]. Ugeskr Laeger (1993) 1.39
Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol (1993) 1.31
Subtypes of Australia antigen among patients and healthy carriers in Copenhagen. A relation between the subtypes and the degree of liver damage in acute viral hepatitis. N Engl J Med (1973) 1.30
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis (2003) 1.29
Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) (1979) 1.28
Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia (2004) 1.28
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab (2001) 1.26
Quantification of intracellular metabolic fluxes from fractional enrichment and 13C-13C coupling constraints on the isotopomer distribution in labeled biomass components. Metab Eng (1999) 1.24
Changes in muscle size and MHC composition in response to resistance exercise with heavy and light loading intensity. J Appl Physiol (1985) (2008) 1.22
Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. Clin Chim Acta (1982) 1.19
Effect of acetyl choline on the secretion of glucagon and insulin from the isolated, perfused canine pancreas. Diabetes (1973) 1.17
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest (1995) 1.17
Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab (2009) 1.17
Nosocomial outbreak of cryptosporidiosis in AIDS patients. BMJ (1991) 1.16
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab (2012) 1.15
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.14
Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. AIDS (1989) 1.14
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab (2003) 1.13
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia (2007) 1.13
Smoking reduces insulin absorption from subcutaneous tissue. Br Med J (Clin Res Ed) (1982) 1.12
Leptospira interrogans serotype pomona in Saskatchewan: isolation from a naturally infected striped skunk. Can J Microbiol (1977) 1.12
The effect of intense exercise on postprandial glucose homeostasis in type II diabetic patients. Diabetologia (1999) 1.12
Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J Virol (1991) 1.11
Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis (2011) 1.11
Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia (2009) 1.11
The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology (2000) 1.11
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut (1999) 1.11
Hypomagnesemia, a risk factor in diabetic retinopathy. Diabetes (1978) 1.11
Pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas. Diabetologia (1978) 1.10
Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) (2013) 1.10
Elective laparoscopic cholecystectomy nearly abolishes the postoperative hepatic catabolic stress response. Ann Surg (1995) 1.09
Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis (1992) 1.09
Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch Virol (1994) 1.08
Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab (1981) 1.08
Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia (2010) 1.08
Immunological studies of Australia antigen carriers with and without liver diseases. Clin Exp Immunol (1973) 1.07
The Ibc protein fraction of group B streptococci: characterization of protein antigens extracted by HCL. Acta Pathol Microbiol Scand B (1981) 1.07
Hormonal, metabolic, and cardiovascular responses to hypoglycemia in diabetic autonomic neuropathy. Diabetes (1981) 1.07
Impaired response of pancreatic polypeptide to hypoglycaemia: an early sign of autonomic neuropathy in diabetics. Br Med J (1979) 1.07
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med (2011) 1.07
Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients. Clin Microbiol Infect (2005) 1.06
An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol (1992) 1.06
Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. Eur J Clin Invest (1982) 1.05
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care (2001) 1.05
Poor reproducibility of Evans' classification of the trochanteric fracture. Assessment of 4 observers in 52 cases. Acta Orthop Scand (1993) 1.05
Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia (2004) 1.05
Delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers. Hepatology (1987) 1.05
Rat liver regeneration after 90% partial hepatectomy. Hepatology (1984) 1.05